---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196513"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:55:35.380421+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viridian Q2 net loss $65M; THRIVE topline readout on track for Sept 2024; cash $571.4M

## Summary
- Net loss of $65.0M in Q2 2024 vs $55.1M Q2 2023; cash balance $571.4M as of June 30, 2024.
- THRIVE phase 3 (active TED) topline data for VRDN-001 expected September 2024.
- THRIVE-2 (chronic TED) enrollment completed with 188 patients, exceeding 159 target; topline due year-end 2024.
- REVEAL-1 and REVEAL-2 phase 3 trials for subcutaneous VRDN-003 to initiate August 2024; topline data H1 2026.
- IND for VRDN-006 (FcRn inhibitor) on track for year-end 2024; NHP data for VRDN-008 expected H2 2024.

## SEC filing metadata
- accession: 0001193125-24-196513
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524196513/0001193125-24-196513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524196513/d879446d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196513
- JSON: https://secwatch.observer/filing/0001193125-24-196513.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.